Rapamycin improves peripheral nerve myelination while it fails to benefit neuromuscular performance in neuropathic mice

Neurobiology of Disease

Volumn 70, Issue , 2014, Pages 224-236

  Nicks, Jessica ^a   Lee, Sooyeon ^a   Harris, Andrew ^a   Falk, Darin J ^a   Todd, Adrian G ^a   Arredondo, Karla ^a   Dunn Jr , William A ^a   Notterpek, Lucia ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Autophagy; Charcot Marie Tooth disease; Demyelination; Myelin; Schwann cell; Trembler J

Indexed keywords

MYELIN; PLACEBO; RAPAMYCIN; BIOLOGICAL MARKER; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MUSCLE RING FINGER 1 PROTEIN; MYELIN BASIC PROTEIN; MYELIN PROTEIN; NEUROTROPHIN RECEPTOR P75; PHOSPHO HISTONE H3; PHOSPHO S6; PROTEIN 0; PROTEIN LIGHT CHAIN 3; PROTEIN P62; RIBOSOMAL PROTEIN SUBUNIT S6; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BEHAVIOR; BODY WEIGHT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG MECHANISM; FEMALE; FRACTIONATION; HEREDITARY MOTOR SENSORY NEUROPATHY; LOCOMOTION; MALE; MORPHOLOGY; MOUSE; MYELINATION; NEUROMUSCULAR FUNCTION; NONHUMAN; PERIPHERAL NERVE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; SCHWANN CELL; SCIATIC NERVE; WILD TYPE; AGE; ANIMAL CELL; AUTOPHAGY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; IN VIVO STUDY; LIVER; LONG TERM CARE; LOW DRUG DOSE; MUSCLE INNERVATION; PERIPHERAL NERVE MYELINATION; SHORT COURSE THERAPY; SOLEUS MUSCLE; TASK PERFORMANCE; ANIMAL; C57BL MOUSE; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECTS; INTRAPERITONEAL DRUG ADMINISTRATION; MOTOR ACTIVITY; MUTATION; MYELIN SHEATH; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSIOLOGY; RANDOMIZATION; SKELETAL MUSCLE; TISSUE CULTURE TECHNIQUE;

ANIMALS; CHARCOT-MARIE-TOOTH DISEASE; COHORT STUDIES; DIETARY SUPPLEMENTS; FEMALE; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MUSCLE, SKELETAL; MUTATION; MYELIN SHEATH; NEURONS; NEUROPROTECTIVE AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; RANDOM ALLOCATION; ROTAROD PERFORMANCE TEST; SCHWANN CELLS; SIROLIMUS; TISSUE CULTURE TECHNIQUES;

EID: 84904875584     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.06.023     Document Type: Article

References (48)

1. Bentzinger C.F., Lin S., Romanino K., Castets P., Guridi M., Summermatter S., Handschin C., Tintignac L.A., Hall M.N., Ruegg M.A. Differential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy. Skelet. Muscle 2013, 3:6.
2. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., Poueymirou W.T., Panaro F.J., Na E., Dharmarajan K., Pan Z.Q., Valenzuela D.M., DeChiara T.M., Stitt T.N., Yancopoulos G.D., Glass D.J. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708.
3. Boger H.A., Mannangatti P., Samuvel D.J., Saylor A.J., Bender T.S., McGinty J.F., Fortress A.M., Zaman V., Huang P., Middaugh L.D., Randall P.K., Jayanthi L.D., Rohrer B., Helke K.L., Granholm A.C., Ramamoorthy S. Effects of brain-derived neurotrophic factor on dopaminergic function and motor behavior during aging. Genes Brain Behav. 2011, 10:186-198.
4. Caccamo A., Majumder S., Richardson A., Strong R., Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 2010, 285:13107-13120.
5. Chong Z.Z., Shang Y.C., Wang S., Maiese K. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog. Neurobiol. 2012, 99:128-148.
6. Forgacs B., Merhav H.J., Lappin J., Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant. Proc. 2005, 37:1912-1914.
7. Fortun J., Dunn W.A., Joy S., Li J., Notterpek L. Emerging role for autophagy in the removal of aggresomes in Schwann cells. J. Neurosci. 2003, 23:10672-10680.
8. Fortun J., Go J.C., Li J., Amici S.A., Dunn W.A., Notterpek L. Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression. Neurobiol. Dis. 2006, 22:153-164.
9. Fortun J., Verrier J.D., Go J.C., Madorsky I., Dunn W.A., Notterpek L. The formation of peripheral myelin protein 22 aggregates is hindered by the enhancement of autophagy and expression of cytoplasmic chaperones. Neurobiol. Dis. 2007, 25:252-265.
10. Hanemann C.O., D'Urso D., Gabreels-Festen A.A., Muller H.W. Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot-Marie-Tooth type 1A. Brain 2000, 123(Pt 5):1001-1006.
11. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., Pahor M., Javors M.A., Fernandez E., Miller R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
12. Ichimura Y., Komatsu M. Selective degradation of p62 by autophagy. Semin. Immunopathol. 2010, 32:431-436.
13. Ingram D.K., Zhu M., Mamczarz J., Zou S., Lane M.A., Roth G.S., deCabo R. Calorie restriction mimetics: an emerging research field. Aging Cell 2006, 5:97-108.
14. Jessen K.R., Mirsky R. Schwann cells and their precursors emerge as major regulators of nerve development. Trends Neurosci. 1999, 22:402-410.
15. Kim S.G., Buel G.R., Blenis J. Nutrient regulation of the mTOR complex 1 signaling pathway. Mol Cells 2013, 35(6):463-473.
16. Klionsky D.J., et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012, 8:445-544.
17. Koyama S., Hata S., Witt C.C., Ono Y., Lerche S., Ojima K., Chiba T., Doi N., Kitamura F., Tanaka K., Abe K., Witt S.H., Rybin V., Gasch A., Franz T., Labeit S., Sorimachi H. Muscle RING-finger protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis. J. Mol. Biol. 2008, 376:1224-1236.
18. Kubota H., Matsumoto S., Yokota S., Yanagi H., Yura T. Transcriptional activation of mouse cytosolic chaperonin CCT subunit genes by heat shock factors HSF1 and HSF2. FEBS Lett. 1999, 461:125-129.
19. Lamming D.W., Ye L., Sabatini D.M., Baur J.A. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J. Clin. Invest. 2013, 123:980-989.
20. Lee S., Notterpek L. Dietary restriction supports peripheral nerve health by enhancing endogenous protein quality control mechanisms. Exp. Gerontol. 2013, 48:1085-1090.
21. Madorsky I., Opalach K., Waber A., Verrier J.D., Solmo C., Foster T., Dunn W.A., Notterpek L. Intermittent fasting alleviates the neuropathic phenotype in a mouse model of Charcot-Marie-Tooth disease. Neurobiol. Dis. 2009, 34:146-154.
22. Malagelada C., Jin Z.H., Jackson-Lewis V., Przedborski S., Greene L.A. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J. Neurosci. 2010, 30:1166-1175.
23. Martini R., Schachner M. Molecular bases of myelin formation as revealed by investigations on mice deficient in glial cell surface molecules. Glia 1997, 19:298-310.
24. Mattson M.P. Dietary factors, hormesis and health. Ageing Res. Rev. 2008, 7:43-48.
25. Meekins G.D., Emery M.J., Weiss M.D. Nerve conduction abnormalities in the trembler-j mouse: a model for Charcot-Marie-Tooth disease type 1A?. J. Peripher. Nerv. Syst. 2004, 9:177-182.
26. Meikle L., Pollizzi K., Egnor A., Kramvis I., Lane H., Sahin M., Kwiatkowski D.J. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 2008, 28:5422-5432.
27. Mizushima N., Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007, 3:542-545.
28. Narayanan S.P., Flores A.I., Wang F., Macklin W.B. Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J. Neurosci. 2009, 29:6860-6870.
29. Nicks J.R., Lee S., Kostamo K.A., Harris A.B., Sookdeo A.M., Notterpek L. Long-term analyses of innervation and neuromuscular integrity in the Trembler-J mouse model of Charcot-Marie-Tooth disease. J. Neuropathol. Exp. Neurol. 2013, 72:942-954.
30. Niemann S., Sereda M.W., Rossner M., Stewart H., Suter U., Meinck H.M., Griffiths I.R., Nave K.A. The "CMT rat": peripheral neuropathy and dysmyelination caused by transgenic overexpression of PMP22. Ann. N. Y. Acad. Sci. 1999, 883:254-261.
31. Nishimura T., Yoshikawa H., Fujimura H., Sakoda S., Yanagihara T. Accumulation of peripheral myelin protein 22 in onion bulbs and Schwann cells of biopsied nerves from patients with Charcot-Marie-Tooth disease type 1A. Acta Neuropathol. 1996, 92:454-460.
32. Notterpek L., Shooter E.M., Snipes G.J. Upregulation of the endosomal-lysosomal pathway in the trembler-J neuropathy. J. Neurosci. 1997, 17:4190-4200.
33. Pareek S., Notterpek L., Snipes G.J., Naef R., Sossin W., Laliberte J., Iacampo S., Suter U., Shooter E.M., Murphy R.A. Neurons promote the translocation of peripheral myelin protein 22 into myelin. J. Neurosci. 1997, 17:7754-7762.
34. Parzych K.R., Klionsky D.J. An overview of autophagy: morphology, mechanism, and regulation. Antioxid. Redox Signal. 2014, 20(3):460-473.
35. Quy P.N., Kuma A., Pierre P., Mizushima N. Proteasome-dependent activation of mammalian target of rapamycin complex 1 (mTORC1) is essential for autophagy suppression and muscle remodeling following denervation. J. Biol. Chem. 2013, 288:1125-1134.
36. Rangaraju S., Notterpek L. Autophagy aids membrane expansion by neuropathic Schwann cells. Autophagy 2011, 7:238-239.
37. Rangaraju S., Verrier J.D., Madorsky I., Nicks J., Dunn W.A., Notterpek L. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice. J. Neurosci. 2010, 30:11388-11397.
38. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., Rubinsztein D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
39. Rubinsztein D.C., Codogno P., Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 2012, 11:709-730.
40. Sarkar S., Rubinsztein D.C. Small molecule enhancers of autophagy for neurodegenerative diseases. Mol. Biosyst. 2008, 4:895-901.
41. Sherman D.L., Krols M., Wu L.M., Grove M., Nave K.A., Gangloff Y.G., Brophy P.J. Arrest of myelination and reduced axon growth when Schwann cells lack mTOR. J. Neurosci. 2012, 32:1817-1825.
42. Shoji-Kawata S., Sumpter R., Leveno M., Campbell G.R., Zou Z., Kinch L., Wilkins A.D., Sun Q., Pallauf K., MacDuff D., Huerta C., Virgin H.W., Helms J.B., Eerland R., Tooze S.A., Xavier R., Lenschow D.J., Yamamoto A., King D., Lichtarge O., Grishin N.V., Spector S.A., Kaloyanova D.V., Levine B. Identification of a candidate therapeutic autophagy-inducing peptide. Nature 2013, 494:201-206.
43. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin. Genet. 1974, 6:98-118.
44. Srivastava S., Haigis M.C. Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer's and Parkinson's diseases. Curr. Pharm. Des. 2011, 17:3418-3433.
45. Suter U., Moskow J.J., Welcher A.A., Snipes G.J., Kosaras B., Sidman R.L., Buchberg A.M., Shooter E.M. A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4382-4386.
46. Tyler W.A., Gangoli N., Gokina P., Kim H.A., Covey M., Levison S.W., Wood T.L. Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J. Neurosci. 2009, 29:6367-6378.
47. Young P., Suter U. The causes of Charcot-Marie-Tooth disease. Cell. Mol. Life Sci. 2003, 60:2547-2560.
48. Zhang Y., Bokov A., Gelfond J., Soto V., Ikeno Y., Hubbard G., Diaz V., Sloane L., Maslin K., Treaster S., Rendon S., van Remmen H., Ward W., Javors M., Richardson A., Austad S.N., Fischer K. Rapamycin extends life and health in C57BL/6 mice. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69(2):119-130.